Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
LongBio Pharma›
News
AddedJul 2, 2026
UpdatedJul 2, 2026
LongBio Pharma

LongBio Pharma

Series C

LongBio Pharma is a clinical-stage biopharmaceutical company developing innovative biologics for allergic and autoimmune diseases.

HQ
Changshu, Jiangsu, CN
Founded
2020
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Latest News About LongBio Pharma

Chinese biotech startup LongBio Pharma lists on Hong Kong stock exchange

BioSpectrum Asia

Chinese biotech startup LongBio Pharma lists on Hong Kong stock exchange

LongBio Pharma, a portfolio company of Qiming Venture Partners, listed on the Hong Kong Stock Exchange. Qiming invested in the B2 round as...

Jun 8, 2026

China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange

PR Newswire

China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange

LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and autoimmune diseases...

Jun 5, 2026

Longbio to raise HK$1.4B in Hong Kong IPO for immunology work

BioWorld

Longbio to raise HK$1.4B in Hong Kong IPO for immunology work

Chinese biotech Longbio Pharma announced its IPO on HKEX to raise HK$1.362 billion (US$174 million) to progress LP-003 next-gen anti-IgE...

May 28, 2026

Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®

PR Newswire

Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®

LongBio announced positive topline results from Phase II trial of LP-003 vs Xolair (omalizumab) in CSU. LP-003 demonstrated comprehensive...

Mar 2, 2026

Breakthrough! Exciting interim Phase II Data of LP-003 in CSU released by Longbio at AAAAI 2025

PR Newswire

Breakthrough! Exciting interim Phase II Data of LP-003 in CSU released by Longbio at AAAAI 2025

LongBio released interim analysis of CSU Phase II data for LP-003 at AAAAI 2025. Demonstrated superior improvement vs Omalizumab in UAS7...

Mar 2, 2025

LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners

PR Newswire

LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners

LongBio Pharma completed Series B2 financing round, raising tens of millions of RMB. Led by Qiming Venture Partners, with continued support...

Sep 24, 2024